RO-28-1675, a glucokinase activator originally developed as an allosteric activator of glucokinase for diabetes treatment [109], may induce anti-ATL activity through ferroptosis, possibly due to its role in enhancing glycolytic activity in response to hepatitis virus infection in liver cells [110]. The gene discussed is GCK; the disease is diabetes mellitus.